Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
STOK · Why this verdict
Why Stoke Therapeutics (STOK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's entire value is concentrated in one drug candidate, zorevunersen, meaning any clinical setback would eliminate the investment thesis entirely. Bear case | Clinical trial data or regulatory filings for zorevunersen advance without a safety or efficacy hold over the next 12 months. | →Stable |
| CounterSingle-asset biotech companies can succeed precisely because all resources focus on one program, avoiding diversification penalties. | ||
Business quality scores 2.8 out of 10, far below the minimum 4.0 threshold, driven by a free cash flow deficit of negative 276% relative to revenue and a weak Piotroski F-Score of 3 out of 9. Quality breakdown | Cash burn rate narrows so that free cash flow as a percentage of revenue improves from negative 276% toward negative 150% or better within 12 months. | →Stable |
| CounterPre-revenue biotechs routinely burn cash; the quality floor is calibrated for operating companies, and a pipeline-stage firm with adequate liquidity (current ratio of 5) can sustain this burn. | ||
Short interest stands at 19%, signaling that a substantial portion of market participants expect the stock to decline, creating potential for forced selling pressure or a squeeze depending on clinical news. Key risks | Short interest falls below 12% as clinical progress reduces bearish conviction over the next 12 months. | →Stable |
| CounterHigh short interest can act as a contrarian indicator; if positive trial data arrives, short covering could accelerate price gains significantly. | ||
Analyst consensus projects roughly 50% upside to a price target around $39, yet the company fails fundamental quality gates and carries no buy confidence, creating a wide gap between analyst optimism and business reality. Sentiment breakdown | The stock price rises above $36 within 12 months if clinical milestones validate analyst targets. | →Stable |
| CounterAnalyst coverage for small biotechs is often optimistic; with only 10 analysts following the stock and a dampened signal, the consensus may overstate the probability of success. | ||
The company's entire value is concentrated in one drug candidate, zorevunersen, meaning any clinical setback would eliminate the investment thesis entirely.
→StableBear case
- Expectation
- Clinical trial data or regulatory filings for zorevunersen advance without a safety or efficacy hold over the next 12 months.
CounterSingle-asset biotech companies can succeed precisely because all resources focus on one program, avoiding diversification penalties.
Business quality scores 2.8 out of 10, far below the minimum 4.0 threshold, driven by a free cash flow deficit of negative 276% relative to revenue and a weak Piotroski F-Score of 3 out of 9.
→StableQuality breakdown
- Expectation
- Cash burn rate narrows so that free cash flow as a percentage of revenue improves from negative 276% toward negative 150% or better within 12 months.
CounterPre-revenue biotechs routinely burn cash; the quality floor is calibrated for operating companies, and a pipeline-stage firm with adequate liquidity (current ratio of 5) can sustain this burn.
Short interest stands at 19%, signaling that a substantial portion of market participants expect the stock to decline, creating potential for forced selling pressure or a squeeze depending on clinical news.
→StableKey risks
- Expectation
- Short interest falls below 12% as clinical progress reduces bearish conviction over the next 12 months.
CounterHigh short interest can act as a contrarian indicator; if positive trial data arrives, short covering could accelerate price gains significantly.
Analyst consensus projects roughly 50% upside to a price target around $39, yet the company fails fundamental quality gates and carries no buy confidence, creating a wide gap between analyst optimism and business reality.
→StableSentiment breakdown
- Expectation
- The stock price rises above $36 within 12 months if clinical milestones validate analyst targets.
CounterAnalyst coverage for small biotechs is often optimistic; with only 10 analysts following the stock and a dampened signal, the consensus may overstate the probability of success.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Stoke Therapeutics is a single-asset biotechnology company with zorevunersen as its only pipeline candidate, offering a high-risk binary outcome; analyst consensus sees roughly 50% upside but quality metrics are critically weak and 19% short interest reflects market skepticism.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -276% of revenue
- ▸No competitive moat
- ▸Rule of 40: -373 (fail)
- ▸Weak Piotroski F-Score: 3/9
Growth
5.0/10data confidence 50%Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.3 |
- ▸Overbought (RSI 75)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 8.2 |
| Price target | 9.1 |
- ▸LLM news sentiment: +0.70 (n=1)
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 38%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸Insider selling (low materiality) — $172,076 (0.008% of mkt cap)
Peer rank
2.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.8 |
| quality rank | 3.3 |
| growth rank | 0.1 |
Technical
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.0 |
| support resistance | 1.5 |
| 52w position | 6.3 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.5 |
| days to cover | 0.0 |
| volatility | 1.2 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 6.3 |
| debt equity | 5.8 |
| news risk | 6.0 |
- ▸High short interest justified: 20%
- ▸High IV: 93%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.5 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- MOMENTUM:7.3>=5.5
- INSIDER:OK
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:1.4<1.5@spot
- 8K_CRITICAL:4.01
Warning (0)
none
Reward-to-Risk
1.43
Upside
+20.0%
Downside
14.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 8.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.4<1.5@spot.
The strongest dimensions are Sentiment at 8.5, Value at 7.5, and Momentum at 7.3; the weakest are Peer rank at 2.5, Quality at 2.8, and Technical at 2.9. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 1.43 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Risk
Trip ifPrice drops below $20, more than 33% below the current $30, following a clinical hold or negative trial readout for zorevunersen.
- P2Critical Quality Shortfall
Trip ifCash and equivalents fall below $50 million, indicating the company has less than 12 months of runway at the current burn rate.
- P3High Short Interest Overhang
Trip ifShort interest rises above 25% of float, increasing the probability that forced selling exceeds 19% current levels.
- P4Analyst Upside Vs Fundamentals
Trip ifAnalyst consensus price target falls below $30, at least equal to the current price of $30, eliminating the projected upside entirely.